Paragon Gene Therapy, a newly acquired unit of contract manufacturer Catalent, will take over the leases of two Novavax facilities, paying the vaccine developer $18 million to acquire related manufacturing equipment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,